GO-203-2C + Bortezomib For Relapsed Or Refractory MM

NCT02658396 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study was never open due to lack of funding

Conditions

Multiple Myeloma
Multiple Myeloma in Relapse
Refractory Multiple Myeloma

Interventions

DRUG: GO-203-2C
DRUG: Bortezomib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]